

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/140358 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61K 31/4745 (2006.01)
C07K 16/28 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2024/142547

(22) International Filing Date:

26 December 2024 (26.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/142398

27 December 2023 (27.12.2023) CN

(71) Applicants: **GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.** [CN/CN]; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **AIMED BIO INC.** [KR/KR]; 11th FL., MK Tower Bldg., 67, Jeongui-ro, Songpa-gu, Seoul 05835 (KR).

(72) Inventors: **QIN, Gang**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **SONG, Paul H.**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **MIN, Byeongkwi**; 11th FL., MK Tower Bldg., 67, Jeongui-ro, Songpa-gu, Seoul 05835 (KR). **LI, XueSong**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing

Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: A PHARMACEUTICAL COMPOSITION OF ANTI-FGFR3 ANTIBODY DRUG CONJUGATE AND APPLICATIONS THEREOF




Figure 2

(57) Abstract: Provided is a pharmaceutical composition comprising conjugates containing anti-FGFR3 antibodies and linker-payloads, the corresponding pharmaceutical composition, preparing process and use thereof.

WO 2025/140358 A1